Recurrence risk factors analysis for stage I Non-small Cell Lung Cancer

Medicine (United States)

Volumn 94, Issue 32, 2015, Pages

  Wu, Ching Feng ^a   Fu, Jui Ying ^b   Yeh, Chi Ju ^a   Liu, Yun Hen ^a   Hsieh, Ming Ju ^a   Wu, Yi Cheng ^a   Wu, Ching Yang ^a   Tsai, Ying Huang ^a   Chou, Wen Chi ^a   Pezzilli, Raffaele ^c  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b Department of Internal Medicine   (Taiwan)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SIZE; CANCER SURGERY; CANCER SURVIVAL; DISEASE FREE SURVIVAL; DISTANT METASTASIS; FEMALE; HIGH RISK PATIENT; HUMAN; INTERMEDIATE RISK PATIENT; LOW RISK PATIENT; LUNG ADENOCARCINOMA; LUNG RESECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PLEURA METASTASIS; POST TREATMENT SURVIVAL; POSTOPERATIVE PERIOD; PRIMARY TUMOR; PRIORITY JOURNAL; RECURRENCE RISK; RETROSPECTIVE STUDY; SMOKING; SURVIVAL RATE; SURVIVAL TIME; TUMOR INVASION; VISCERAL METASTASIS; CANCER STAGING; CARCINOMA, NON-SMALL-CELL LUNG; LUNG NEOPLASMS; MIDDLE AGED; PATHOLOGY; PROGNOSIS; RISK FACTOR; TUMOR RECURRENCE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; RISK FACTORS; SMOKING;

EID: 84942432074     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000001337     Document Type: Article

References (29)

1. American Joint Committee on Cancer (AJCC) cancer staging handbook. In: Edge SB, Byrd DR, Compton CC, et al, eds. AJCC Cancer Staging Manual. 7th ed. Chicago: Springer; 2010: 299-323.
2. National comprehensive cancer network guideline version 2. 2013.
3. Kelsey CR, Marks LB, Hollis D, et al. Local recurrence after surgery for early stage lung. Cancer. 2009; 115: 5218-5227.
4. Guerreraa F, Erricob L, Evangelistac A, et al. Exploring stage I non-small-cell lung cancer: development of a prognostic model predicting 5-year survival after surgical resection. Eur J Cardiothorac Surg. 2014; 6: 1037-1043.
5. Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled by the LACE Collaborative Group. J Clin Oncol. 2008; 26: 3552-3559.
6. Tsutani Y, Miyata Y, Kushitani K, et al. Propensity score-matched analysis of adjuvant chemotherapy for stage I non-small cell lung cancer. J Thorac Cardiovasc Surg. 2014; 148: 1179-1185.
7. Kato H, Ichinose Y, Ohta M, et al. Japan Lung Cancer Research Group on Postsurgical Adjuvant Chemotherapy. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med. 2004; 350: 1713-1721.
8. Hamada C, Tsuboi M, Ohta M, et al. Effect of postoperative adjuvant chemotherapy with tegafur-uracil on survival in patients with stage IA non-small cell lung cancer: an exploratory analysis from a meta-analysis of six randomized controlled trials. J Thorac Oncol. 2009; 4: 1511-1516.
9. Tanaka F, Wada H, Fukushima M. UFT and S-1 for treatment of primary lung cancer. Gen Thorac Cardiovasc Surg. 2010; 58: 3-13.
10. Travis WD, Brambilla E, Rami-Porta R, et al. International Staging Committee. Visceral pleural invasion: pathologic criteria and use of elastic stains. Proposal for the 7th edition of the TNM classification for lung cancer. J Thorac Oncol. 2008; 3: 1384-1390.
11. Shimizu K, Yoshida J, Nagai K, et al. Visceral pleural invasion is an invasive and aggressive indicator of non-small cell lung cancer. J Thorac Cardiovasc Surg. 2005; 130: 160-165.
12. Schuchert MJ, Schumacher L, Kilic A, et al. Impact of angiolymphatic and pleural invasion on surgical outcomes for stage I non-small cell lung cancer. Ann Thorac Surg. 2011; 91: 1059-1065.
13. Kato T, Ishikawa K, Aragaki M, et al. Angiolymphatic invasion exerts a strong impact on surgical outcomes for stage I lung adenocarcinoma, but not non-adenocarcinoma. Lung Cancer. 2012; 77: 394-400.
14. Arame A, Mordant P, Cazes A, et al. Characteristics and prognostic value of lymphatic and blood vascular microinvasion in lung cancer. Ann Thorac Surg. 2012; 94: 1673-1679.10.
15. Park SY, Lee HS, Jang HJ, et al. Tumor necrosis as a prognostic factor for stage IA non-small cell lung cancer. Ann Thorac Surg. 2011; 91: 1668-1673.
16. Riquet M, Legras A, Mordant P, et al. Number of mediastinal lymph nodes in non-small cell lung cancer: a gaussian curve, not a prognostic factor. Ann Thorac Surg. 2014; 98: 224-231.
17. Chang MY, Mentzer J, Colson YL, et al. Factors predicting poor survival after resection of stage IA non-small cell lung cancer. J Thorac Cardiovasc Surg. 2007; 134: 850-856.
18. Asamura H, Goya T, Koshiishi Y, et al. A Japanese Lung Cancer Registry study: prognosis of 13,010 resected lung cancers. J Thorac Oncol. 2008; 3: 46-52.
19. Peters S, Weder W, Dafni U, et al. Lungscape: resected non-small-cell lung cancer outcome by clinical and pathological parameters. J Thorac Oncol. 2014; 9: 1675-1684.
20. Son C, Lee SK, Choi PJ, et al. Characteristics of additional primary malignancies in Korean patients with non-small cell lung cancer. J Thorac Dis. 2013; 5: 737-744.
21. Brock MV, Alberg AJ, Hooker CM, et al. Risk of subsequent primary neoplasms developing in lung cancer patients with prior malignancies. J Thorac Cardiovasc Surg. 2004; 127: 1119-1125.
22. Cho I, An JY, Kwon IG, et al. Risk factors for double primary malignancies and their clinical implications in patients with sporadic gastric cancer. Eur J Surg Oncol. 2014; 40: 338-344.
23. Poullis M, Shackcloth M, Page R, et al. Metastatic index of non-small-cell lung cancer and long-term survival. Asian Cardiovasc Thorac Ann. 2015: 185-190.
24. Poullis M, McShane J, Shaw M, et al. Smoking status at diagnosis and histology type as determinants of long-term outcomes of lung cancer patients. Eur J Cardiothorac Surg. 2013; 43: 919-924.
25. Fry JS, Lee PN, Forey BA, et al. Is the shape of the decline in risk following quitting smoking similar for squamous cell carcinoma and adenocarcinoma of the lung? A quantitative review using the negative exponential model. Regul Toxicol Pharmacol. 2015; 72: 49-57.
26. Koike T, Koike T, Yoshiya K, et al. Risk factor analysis of locoregional recurrence after sublobar resection in patients with clinical stage IA non-small cell lung cancer. J Thorac Cardiovasc Surg. 2013; 146: 372-378.
27. Yamamoto K, Ohsumi A, Kojima F, et al. Long-term survival after video-assisted thoracic surgery lobectomy for primary lung cancer. Ann Thorac Surg. 2010; 89: 353-359.
28. Higuchi M, Yaginuma H, Yonechi A, et al. Long-term outcomes after video-assisted thoracic surgery (VATS) lobectomy versus lobectomy via open thoracotomy for clinical stage IA non-small cell lung cancer. J Cardiothorac Surg. 2014; 9: 88.
29. Vallières E, Shepherd FA, Crowley J, et al. The IASLC Lung Cancer Staging Project: proposals regarding the relevance of TNM in the pathologic staging of small cell lung cancer in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol. 2009; 4: 1049-1059.